Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Kuan-Ting Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institutes of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Glioblastoma, Cell Cycle Checkpoints, Gene Expression Regulation, Neoplastic, Cdc20 Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Kaohsiung Municipal Siaogang Hospital, I-Shou University.
Abstract (Originalsprache)
Omaveloxolone is a synthetic oleanane triterpene with considerable antitumor activity. It induces human glioblastoma (GBM) cell death in vitro and in vivo, but the underlying mechanism remains to be determined. In this study, GBM cell lines (GBM8401 and U‐87 MG cells) were exposed to different concentrations of omaveloxolone (0, 600, 800 and 1000 nM). A cell viability assay was conducted using the PrestoBlue Cell Viability Reagent. Three‐dimensional microscopy revealed changes in cell morphology. Cell cycle, apoptosis and mitochondrial membrane potential were tested using flow cytometry. The expression levels of cell cycle‐related proteins and genes were determined through Western blotting and next‐generation sequencing, respectively. The results indicated that omaveloxolone had significant selective cytotoxicity against human GBM cells and suppressed the migration and invasion of these cancer cells. It also caused cell cycle arrest through the downregulation of cell cycle‐related genes, including cell division cycle 20 homologue ( CDC20 ), as revealed by next‐generation sequencing. In a xenograft tumour model, omaveloxolone decreased tumour volume and CDC20 expression. Taken together, these findings suggest that omaveloxolone is a potential drug candidate for GBM treatment by promoting GBM cell death through the downregulation of CDC20 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institutes of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- School of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Surgery, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Surgery, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.
ORCID-Profile: Tai-Hsin Tsai
Förderung
- National Science and Technology Council
- Kaohsiung Municipal Siaogang Hospital
- I-Shou University
- E-Da Cancer Hospital
Zitieren
APA
Lee, K. T., Hsu, Y. C., Lieu, A. S., Lin, C. L., & Tsai, T. H. (2025). Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70607
Vancouver
Lee KT, Hsu YC, Lieu AS, Lin CL, Tsai TH. Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70607
BibTeX
@article{Lee2025,
author = {Lee, Kuan-Ting and Hsu, Yi-Chiang and Lieu, Ann-Shung and Lin, Chih-Lung and Tsai, Tai-Hsin},
title = {Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70607}
}
EUVIMED